ABSTRACT: Background Biomarkers are key tools in cancer management. In neuroendocrine tumors (NETs), Chromogranin A (CgA) was considered acceptable as a biomarker. We assessed the clinical efficacy of a multigenomic blood biomarker (NETest) to CgA over a 5-year period. Methods An observational, prospective, cross-sectional, multicenter, multinational, comparative cohort assessment. Cohort #1: NETest evaluation in NETs (1,684) and cancers, benign diseases, controls (731).